Table 2:

Treatment-related adverse events occurring at any grade in ≥10% of patients in any cohort or at grade ≥3 in any patient

	1 mg/kg dose (n=4)			3 mg/kg dose (n=13)			10 mg/kg dose (n=15)			20 mg/kg dose (n=21)
	Grade 1–2	Grade 3	Grade 4	Grade 1–2	Grade 3	Grade 4	Grade 1–2	Grade 3	Grade 4	Grade 1–2	Grade 3	Grade 4
Fatigue	0	0	0	5 (39%)	0	0	10 (67%)	1 (7%)	0	5 (24%)	0	0
Influenza-like illness	1 (25%)	0	0	1 (8%)	0	0	3 (20%)	0	0	6 (29%)	0	0
Pyrexia	2 (50%)	0	0	2 (15%)	0	0	4 (27%)	0	0	0	0	0
Chills	2 (50%)	0	0	0	0	0	2 (13%)	0	0	2 (10%)	0	0
Allergic rhinitis	0	0	0	2 (15%)	0	0	1 (7%)	0	0	1 (5%)	0	0
Increased blood creatine phosphokinase	0	0	0	0	0	0	1 (7%)	0	0	1 (5%)	1 (5%)	1 (5%)
Diarrhoea	1 (25%)	0	0	0	0	0	2 (13%)	0	0	1 (5%)	0	0
Infusion-related reaction	0	0	0	0	0	0	1 (7%)	0	0	3 (14%)	0	0
Lymphopenia	0	0	0	2 (15%)	0	0	2 (13%)	0	0	0	0	0
Decreased lymphocyte count	0	0	0	2 (15%)	0	0	1 (7%)	1 (7%)	0	0	0	0
Myalgia	1 (25%)	0	0	1 (8%)	0	0	0	0	0	2 (10%)	0	0
Increased aspartate aminotransferase	1 (25%)	1 (25%)	0	0	0	0	0	1 (7%)	0	0	0	0
Autoimmune disorder	0	0	0	0	0	0	0	1 (7%)	1 (7%)	0	1 (5%)	0
Hyperglycaemia	1 (25%)	0	0	0	0	0	2 (13%)	0	0	0	0	0
Increased lipase	0	0	0	0	0	0	0	0	0	2 (10%)	1 (5%)	0
Nausea	0	0	0	0	0	0	2 (13%)	0	0	1 (5%)	0	0
Rash	1 (25%)	0	0	0	0	0	1 (7%)	0	0	1 (5%)	0	0
Increased alanine aminotransferase	1 (25%)	0	0	0	0	0	0	1 (7%)	0	0	0	0
Increased amylase	0	0	0	0	0	0	0	0	0	1 (5%)	1 (5%)	0
Hypotension	0	0	0	0	0	0	0	0	0	2 (10%)	0	0
Malaise	1 (25%)	0	0	0	0	0	0	0	0	1 (5%)	0	0
Increased blood alkaline phosphatase	0	1 (25%)	0	0	0	0	0	0	0	0	0	0
Lower abdominal pain	0	0	0	0	0	0	0	1 (7%)	0	0	0	0
Hypocalcaemia	1 (25%)	0	0	0	0	0	0	0	0	0	0	0
Insomnia	1 (25%)	0	0	0	0	0	0	0	0	0	0	0

Data are n (%). No grade 5 treatment-related adverse events occurred.